John Foster, MD
Neurology · Midland, TXNPI 1679568380
Payments from drug & device makers
Across 276 payments — averaging $19.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biogen$502
- UCB, Inc.$496
- AbbVie$466
- Teva Pharmaceuticals USA, Inc.$434
- Novartis$330
- Amgen$275
- plus $3K from 29 others
What the payments were for
- Consulting fees$3006%
- Speaking & faculty fees$130%
- Food & beverage$4,93494%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biogen | 15 | $502 |
| UCB, Inc. | 25 | $496 |
| AbbVie(2 entities) | 31 | $466 |
| Teva Pharmaceuticals USA, Inc. | 29 | $434 |
| Novartis | 23 | $330 |
| Amgen(2 entities) | 14 | $275 |
| Biohaven Pharmaceuticals, Inc. | 11 | $244 |
| Supernus Pharmaceuticals, Inc. | 17 | $238 |
| EMD Serono, Inc. | 10 | $225 |
| Kyowa Kirin, Inc. | 7 | $200 |
| SK Life Science, Inc. | 10 | $196 |
| Pfizer | 10 | $180 |
| Biohaven Pharmaceutical Holding Company Ltd. | 12 | $148 |
| CSL Behring | 2 | $146 |
| Genentech USA, Inc. | 7 | $139 |
| Lilly USA, LLC | 7 | $139 |
| Otsuka America Pharmaceutical, Inc. | 4 | $100 |
| Upsher-smith Laboratories LLC | 5 | $86 |
| Neurelis, Inc. | 3 | $80 |
| Amneal Pharmaceuticals LLC | 5 | $80 |
| Bristol Myers Squibb | 4 | $69 |
| Lundbeck LLC | 4 | $67 |
| Acadia Pharmaceuticals Inc | 3 | $57 |
| Sanofi | 3 | $55 |
| Avanir Pharmaceuticals, Inc. | 3 | $53 |
| Livanova USA, Inc. | 2 | $43 |
| AstraZeneca | 2 | $37 |
| Akcea Therapeutics, Inc. | 1 | $25 |
| Averitas Pharma Inc. | 1 | $24 |
| Argenx US, Inc. | 1 | $23 |
| MDD US Operations, LLC | 1 | $22 |
| Sanofi-aventis U.S. LLC | 1 | $21 |
| Neurocrine Biosciences, Inc. | 1 | $20 |
| Alnylam Pharmaceuticals Inc. | 1 | $19 |
| Acorda Therapeutics, Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TYSABRI$300
- Hizentra$122
- NURTEC ODT$115
- AUSTEDO$104
How this compares
$5,247 in reported general payments places this provider in the 55th percentile of 1,246 neurology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dalfampridine ErDalfampridine | 22 | $13,275 |
| KeppraLevetiracetam | 12 | $13,226 |
| LamictalLamotrigine | 12 | $8,211 |
| Primidone | 50 | $2,278 |
| Levetiracetam | 57 | $2,178 |
| DilantinPhenytoin Sodium Extended | 12 | $1,680 |
| Rasagiline Mesylate | 14 | $1,521 |
| Carbamazepine ErCarbamazepine | 15 | $1,397 |
| Divalproex Sodium | 26 | $1,087 |
| Gabapentin | 56 | $1,066 |
| Carbamazepine | 17 | $814 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 23 | $637 |
| AmantadineAmantadine Hcl | 15 | $330 |
| Memantine Hcl | 12 | $221 |
| Donepezil Hcl | 22 | $220 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerDilantin | $180 | $1,68012 claims |
| Upsher-smith Laboratories LLCTopiramate | $86 | $14015 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,246 neurology providers in Texas.
Other neurology in Midland
- Ann BassSan Antonio$12.3M
- Kandasami SenthilkumarBeaumont$7.6M
- Bharathy SundaramSherman$7.2M
- Bhupesh DiheniaLubbock$6.9M
- Jamshid LotfiHouston$6M
- Nazanin MajdHouston$5.9M
- Aziz ShaibaniHouston$5.5M
- Elizabeth PeckhamRound Rock$5.4M
- Susan IannacconeDallas$5.1M
- Benjamin GreenbergDallas$4.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.